Biotech Values

[mskatiescarletohara]

“several key U.S. macular degeneration clinical trials” in 2004

Sounds agressive to me, it appears they want to enroll the trials in an expedient manner, I also believe it's imperative for GENR to do such if they wish to be competitive with the other ocular studies which are enrolling, one key advantage is MOA.

I would like to know what 'cost per patient' is involved with conducting such trials, and who the manufacturer is for Squalamine. I also believe GENR will have to secure a partnership to move forward at the pace they are implying in today's PR.

I'll be watching to see if Jason Kantor issues any comments on today's report.

katie....